logo

IPCALAB vs JUBLPHARMA: Stock Comparison

IPCA LABORATORIES vs JUBILANT PHARMOVAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

IPCA LABORATORIES is the larger company by market capitalisation. IPCA LABORATORIES shows a lower P/E, a higher ROE and lower leverage, while JUBILANT PHARMOVA shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

IPCALAB leads 8; JUBLPHARMA leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

IPCALABJUBLPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹47,950 Cr
₹14,757 Cr
P/E RatioIPCALAB has the lower reading
36.61x ✓
41.9x
P/B RatioJUBLPHARMA has the lower reading
5.95x
2.08x ✓
EPSIPCALAB has the higher reading
₹15.84 ✓
₹3.55
Book ValueContext only
₹375.4
₹445.48
Dividend YieldJUBLPHARMA has the higher reading
0.31%
0.54% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
IPCALAB is the larger company
₹47,950 Cr vs ₹14,757 Cr
P/E Ratio
IPCALAB has a lower P/E
36.61x vs 41.9x
P/B Ratio
JUBLPHARMA has a lower P/B
2.08x vs 5.95x
EPS
IPCALAB has higher earnings per share
₹15.84 vs ₹3.55
Dividend Yield
JUBLPHARMA has a higher dividend yield
0.54% vs 0.31%
Revenue Growth (TTM YoY)
JUBLPHARMA has faster revenue growth
18.7% vs 6.2%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs -22.4%
ROE
IPCALAB has a higher ROE
12.43% vs 5.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABJUBLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABJUBLPHARMA
Live Price₹1,903.5₹932.2
Day Change-0.8%0.3%
Volume3.27 L1.08 L
52-Week High₹2,038₹1,183
52-Week Low₹1,251.6₹786.05
Distance from 52W High-6.6%-21.2%

Valuation

MetricIPCALABJUBLPHARMA
Market Cap₹47,950 Cr₹14,757 Cr
P/E Ratio36.61x41.9x
P/B Ratio5.95x2.08x
EPS₹15.84₹3.55
Book Value₹375.4₹445.48
Dividend Yield0.31%0.54%

Growth

MetricIPCALABJUBLPHARMA
Revenue Growth (TTM YoY)6.2%18.7%
EPS Growth (TTM YoY)341.6%-22.4%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricIPCALABJUBLPHARMA
ROE12.43%5.6%
ROCE12.76%5.91%
Net Margin11.83%5.28%
Operating Margin17.09%9.98%
Debt to Equity0.07x0.45x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricIPCALABJUBLPHARMA
Promoter Holding44.72%44.39%
FII Holding11.53%▲ 0.8 pp15.87%▼ 0.03 pp
DII Holding36.59%▼ 0.78 pp12.4%▲ 0.78 pp
Public Holding7.15%▼ 0.03 pp23.5%▼ 0.74 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA LABORATORIES and JUBILANT PHARMOVA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.